Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
M.D. Anderson Cancer Center
Hoffmann-La Roche
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
University of Pittsburgh
Genentech, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
University of Colorado, Denver
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
Alliance Foundation Trials, LLC.
SCRI Development Innovations, LLC
Hoffmann-La Roche
Gustave Roussy, Cancer Campus, Grand Paris
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
University Medical Center Groningen